Related references
Note: Only part of the references are listed.Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer
George Fountzilas et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase II study of sunitinib malate in head and neck squamous cell carcinoma
Nicholas W. Choong et al.
INVESTIGATIONAL NEW DRUGS (2010)
Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420
Stephen K. Williamson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Sunitinib in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: GORTEC 2006-01
Jean-Pascal H. Machiels et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck
Emer O. Hanrahan et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2009)
Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
Satoshi Shiono et al.
ANNALS OF THORACIC SURGERY (2009)
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Howard A. Burris et al.
CLINICAL CANCER RESEARCH (2009)
Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck Cancer
Tawee Tanvetyanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study
Ezra E. W. Cohen et al.
LANCET ONCOLOGY (2009)
Burden of Potentially Human Papillomavirus-associated Cancers of the Oropharynx and Oral Cavity in the US, 1998-2003
A. Blythe Ryerson et al.
CANCER (2008)
Randomized Trial of Postoperative Reirradiation Combined With Chemotherapy After Salvage Surgery Compared With Salvage Surgery Alone in Head and Neck Carcinoma
Francois Janot et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer
Marshall R. Posner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
Christine Elser et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Salvage re-irradiation for recurrent head and neck cancer
Nancy Lee et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Multicenter phase II study of combined neoadjuvant docetaxel and androgen ablation (ADT) prior to radical prostatectomy (RP) for patients (pts) with high risk localized prostate cancer (LCaP): Pathologic outcomes and 3-year follow-up analyses
E. Winquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
Matthew G. Fury et al.
INVESTIGATIONAL NEW DRUGS (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck - Southwest Oncology Group study 0007
Francis P. Worden et al.
CANCER (2006)
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma
JK Salama et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
EEW Cohen et al.
CLINICAL CANCER RESEARCH (2005)
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study
B Burtness et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
RS Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the eastern cooperative oncology group
MK Gibson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
D Soulieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
EEW Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer - A phase II feasibility study
J Janinis et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2000)
Share Paper
